Amgen Inc. (NASDAQ:AMGN) Holdings Decreased by Alan B Lancz & Associates Inc.

Alan B Lancz & Associates Inc. reduced its holdings in Amgen Inc. (NASDAQ:AMGN) by 11.3% in the 4th quarter, Holdings Channel reports. The fund owned 10,630 shares of the medical research company’s stock after selling 1,350 shares during the period. Amgen makes up about 2.8% of Alan B Lancz & Associates Inc.’s portfolio, making the stock its 7th biggest position. Alan B Lancz & Associates Inc.’s holdings in Amgen were worth $2,771,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Flagship Harbor Advisors LLC lifted its position in shares of Amgen by 38.3% in the fourth quarter. Flagship Harbor Advisors LLC now owns 2,954 shares of the medical research company’s stock worth $770,000 after purchasing an additional 818 shares in the last quarter. Insight Inv LLC lifted its position in Amgen by 5.4% in the 4th quarter. Insight Inv LLC now owns 7,541 shares of the medical research company’s stock worth $1,965,000 after buying an additional 385 shares in the last quarter. Stewardship Advisors LLC boosted its stake in shares of Amgen by 14.2% during the 4th quarter. Stewardship Advisors LLC now owns 851 shares of the medical research company’s stock valued at $222,000 after buying an additional 106 shares during the period. Vantage Wealth grew its holdings in shares of Amgen by 0.5% during the 4th quarter. Vantage Wealth now owns 66,801 shares of the medical research company’s stock valued at $17,411,000 after acquiring an additional 352 shares in the last quarter. Finally, GSB Wealth Management LLC increased its stake in shares of Amgen by 5.9% in the fourth quarter. GSB Wealth Management LLC now owns 12,978 shares of the medical research company’s stock worth $3,383,000 after acquiring an additional 721 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMGN has been the subject of a number of research reports. Bank of America reissued an “underperform” rating and set a $256.00 price objective on shares of Amgen in a research report on Tuesday, December 10th. Piper Sandler lowered their price target on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. Wolfe Research assumed coverage on shares of Amgen in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. Finally, StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $314.65.

Amgen Stock Performance

NASDAQ:AMGN opened at $275.42 on Friday. The firm’s 50-day moving average is $271.39 and its 200-day moving average is $305.99. The company has a market cap of $148.05 billion, a price-to-earnings ratio of 35.27, a PEG ratio of 2.78 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the previous year, the company posted $4.96 earnings per share. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. Equities research analysts anticipate that Amgen Inc. will post 19.56 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.46%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is presently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.